New hope for macular degeneration patients who failed standard treatments
NCT ID NCT07547228
First seen Apr 25, 2026 · Last updated May 22, 2026 · Updated 4 times
Summary
This early-stage study tests a new drug called PRL3-zumab in 15 people with wet age-related macular degeneration (nAMD) who did not improve with standard treatments. The drug is given through a vein every two weeks for three doses, and patients are monitored for 24 weeks. The goal is to check safety and whether it can improve vision and reduce retinal swelling.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
NUHS Department of Ophthalmology
RECRUITINGSingapore, Singapore
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.